Evidence map›Paper›PMID 32801441›Full record

ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2020

Idiopathic Membranous Nephropathy and Treatment Related Complications.

Snezana Uncanin, Jasminka Dzemidzic, Nafija Serdarevic, Alma Muslimovic, Denis Haskovic

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Snezana UncaninUrology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina and Clinic of Nephrology, Clinics Center, Sarajevo, Bosnia and Herzegovina.
Jasminka DzemidzicUrology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina and Clinic of Nephrology, Clinics Center, Sarajevo, Bosnia and Herzegovina.
Nafija SerdarevicFaculty of Health Studies, University of Sarajevo, Bosnia and Herzegovina.
Alma MuslimovicUrology Clinic, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina and Clinic of Nephrology, Clinics Center, Sarajevo, Bosnia and Herzegovina.
Denis HaskovicInstitute for Clinical Biochemistry and Immunology University of Sarajevo, Clinics Center, Sarajevo, Bosnia and Herzegovina.
University of Sarajevo · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIdiopathic Idiopathic membranous nephropathy (iMN) is an immune-complex mediated renal disease which is usually associated with the nephrotic syndrome (NS). The course of the disease is variable. Some patients maintain normal kidney function with or without a spontaneous remission of proteinuria, while others progress to end-stage renal failure or die from complications related to the nephrotic syndrome. Whether or not to treat a patient with idiopathic membranous nephropathy is still controversial. The controversy is mainly related to the toxicity of the therapy and the variable natural course of the disease-spontaneous remission occurs in 40-50% of patients.

aimThe aim of this study was to describe our experience of treatment of an idiopathic membranous nephropathy (iMN), efficacy and complications rate. CASE REPORT: Our patient was older, mail gender, in high-risk group with persistent proteinuria 10,68 g/day and stable renal function. We have taken these factors into consideration, along with age and other comorbidities, that may significantly elevate the risk of treatment. We chose to start with early treatment, following the Ponticelli's group protocol based on high dose corticosteroids (odd months) alternating with clorambucil (even months) for six months. This treatment was accompanied by the steroid side effects, including hyperglycaemia dependance on insulin therapy and pulmonary thromboembolism despite administered prophylactically low molecular weight heparin. The six-month treatment was successfully completed with the reduction of proteinuria to nephritic values 2,86 g/day, despite many complications. Complete remission of the disease with non-significant proteinuria and with stable renal function was achieved in 14 months which has been maintained for 2 years.

conclusionWe suggest that decisions on the timing of start of therapy, whom to treat, best sequence of the use of the various immunosuppressive drugs must be based on an individualized assessment of risks and benefits.

Indexed as

AnticoagulantsAnti-Inflammatory AgentsAntineoplastic Agents, AlkylatingChlorambucilDrug Therapy, CombinationGlomerulonephritis, MembranousHumansHyperglycemiaMaleMethylprednisoloneMiddle AgedPrednisoneProteinuriaPulmonary EmbolismAnticoagulantsAnti-Inflammatory AgentsAntineoplastic Agents, AlkylatingChlorambucilMethylprednisolonePrednisoneMembranous nephropathyPonticelli’s protocolpulmonary thromboembolism

Identifiers

PMID32801441
PMCPMC7405995
OpenAlexW3036884912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.